Drug Trial Radar · NCT01402986
A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
Last checked: Nov 20, 2026Latest source record: Apr 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
689
Actual
Start
Aug 2011
Primary completion
Jun 2013
Study completion Feb 2014
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 27, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.
Conditions
- Asthma
Interventions
Placebo Q2WOther
Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
Tralokinumab 300 mg, Q2WBiological
Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
Placebo, Q2/4WOther
Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
Tralokinumab 300 mg, Q2/4WBiological
Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual Asthma Exacerbation Rate (AER)Time frame: Week 1 up to Week 53
Locations
89 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Rancho Mirage, California
Research Site
Centennial, Colorado
Research Site
New Haven, Connecticut
Research Site
Cocoa, Florida
Research Site
Miami, Florida
Research Site
Winter Park, Florida
Research Site
Albany, Georgia
Research Site
Fargo, North Dakota
Research Site
Philadelphia, Pennsylvania
Research Site
Upland, Pennsylvania
Research Site
Killeen, Texas
Research Site
Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Monte Grande, Argentina
Research Site
Ranelagh, Argentina
Research Site
Rosario, Argentina
Research Site
Calgary, Alberta, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Quillota, Chile
Research Site
Santiago, Chile
Research Site
Valparaíso, Chile
Research Site
Viña del Mar, Chile
Research Site
Jindřichův Hradec, Czechia
Research Site
Pilsen, Czechia
Research Site
Rokycany, Czechia
Research Site
Marseille, France
Research Site
Montpellier, France
Research Site
Nantes, France
Research Site
Paris, France
Research Site
Perpignan, France
Research Site
Pessac, France
Research Site
Strasbourg, France
Research Site
Berlin, Germany
Research Site
Frankfurt, Germany
Research Site
Lübeck, Germany
Research Site
Mainz, Germany
Research Site
Chūōku, Japan
Research Site
Fujisawa-shi, Japan
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.